Latest news with #pharmacy
Yahoo
17 hours ago
- Business
- Yahoo
Clover Health (CLOV) Announced a New Pharmacy Pilot Program in New Jersey
Clover Health Investments, Corp. (NASDAQ:CLOV) is one of the . On July 9, Clover Health Investments, Corp. (NASDAQ:CLOV) announced a new pharmacy pilot program in New Jersey. The new program is being launched in partnership with IPC Digital Health, which connects independent community pharmacies across the state. The program is aimed at helping seniors. Management noted that local pharmacies in the iCare+ network will be the backbone of this initiative. As these pharmacies already know their communities and will use new technology and virtual services to assist patients, especially those with chronic health conditions. An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic. A key part of the program is using real-time tools, powered by Clover Health Investments, Corp. (NASDAQ:CLOV)'s data and AI. These tools will monitor if prescriptions are filled and help spot when patients miss doses. Pharmacists will work closely with doctors and care teams to ensure seniors always get the right medicine at the right time, close to where they live. Clover Health Investments, Corp. (NASDAQ:CLOV) is a technology company that helps improve healthcare for people on Medicare, especially seniors. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
2 days ago
- Health
- Yahoo
VytlOne expands partnership with Maury Regional Health
Pharmacy solutions provider VytlOne, previously known as Maxor, is expanding its existing collaboration with US-based Maury Regional Health to launch additional retail pharmacy locations. VytlOne and Maury Regional Health will inaugurate two new retail pharmacy sites by the end of this year, with a third location set to open in the first half of 2026. The move aims to help better serve the community's growing healthcare needs. VytlOne pharmacy services president Joel Wright said: 'We are honoured to be providing pharmacy solutions for Maury Regional Health, supporting their mission and tradition of serving their community with quality and compassionate care. 'Together, we will increase patient access to the highest quality pharmacy services while lowering the overall cost of care.' Maury Regional Health is a not-for-profit health system. Maury Regional Medical Center serves as its flagship hospital and comprises 255 beds. The centre provides a range of advanced services, including a neonatal intensive care unit, an accredited heart programme, and a cancer centre. Maury Regional Health operates hospitals, outpatient facilities, surgery centres, and physician practices across the region. These include Wayne Medical Center in Waynesboro, Marshall Medical Center in Lewisburg, Lewis Health Center in Hohenwald, and Maury Regional Medical Group physician practices. Maury Regional Health chief medical officer Dr Christina Lannom said: 'We have enjoyed partnering with VytlOne to develop an outpatient pharmacy strategy for growth and opening the doors of our first outpatient pharmacy. Our mission has always been to provide a safe, seamless, and patient-centred experience. 'With VytlOne as our ally, we are confident that our patients will receive the highest level of clinical excellence in our pharmacies as they do in our hospitals and clinics.' This year, VytlOne is on track to introduce more than 20 pharmacies in collaboration with hospitals across the US. "VytlOne expands partnership with Maury Regional Health" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medical News Today
2 days ago
- Health
- Medical News Today
Spevigo side effects and how to manage them
As with other drugs, Spevigo (spesolimab-sbzo) can cause side effects, such as injection site reactions and urinary tract infections. If side effects of Spevigo become difficult to tolerate, talk with your doctor or (spesolimab-sbzo) is a brand-name subcutaneous or intravenous (IV) injection prescribed for generalized pustular psoriasis (GPP) in adults and certain you have problems with side effects from Spevigo, talk with your doctor or pharmacist. They can discuss ways to manage side effects or other available treatment options. Do not stop taking Spevigo without consulting your doctor first.»Learn more about Spevigo, including details about its common side effects of SpevigoSpevigo can cause certain side effects, some of which are more common than others. These side effects may be temporary, lasting a few days to weeks. However, if the side effects persist, bother you, or become severe, be sure to talk with your doctor or pharmacist. These are just a few of the more common side effects reported by people who took Spevigo in clinical trials:urinary tract infection (UTI)joint painitchingweaknessfatigueinjection site reactionFor more information about some of these side effects, see the 'Managing side effects' section. Mild side effects of SpevigoMild side effects can occur with Spevigo use. This list may not include all possible mild side effects of the drug. To find out more, you can refer to Spevigo's prescribing side effects that have been reported with Spevigo include:itchingheadachenauseaweaknessfatigueThese side effects may be temporary, lasting a few days to weeks. However, if the side effects continue, worsen, or become too difficult to tolerate, be sure to talk with your doctor or After the Food and Drug Administration (FDA) approves a drug, it tracks and reviews side effects of the medication. Sharing your experience helps make medications safer for everyone by giving doctors and researchers more information about how the drug works in real life. If you develop a side effect while taking Spevigo and want to tell the FDA about it, visit MedWatch or call side effects of SpevigoSpevigo may cause serious side effects. The following list may not include all possible serious side effects of the drug. For more information, you can refer to Spevigo's prescribing you develop serious side effects while taking Spevigo, call your doctor right away. If the side effects seem life threatening or you think you're having a medical emergency, immediately call 911 or your local emergency side effects that have been reported include:active or recurrent infectionsinfusion reactionsAllergic reactionFor some people, Spevigo can cause an allergic side effect was reported in the drug's general, symptoms of allergic reaction can be mild or serious, including a severe allergic reaction called drug rash with eosinophilia and systemic symptoms (DRESS). Ways to manageFor mild allergic reaction symptoms, such as a mild rash, call your doctor right away. They may recommend treatments to help manage your symptoms. They'll also let you know whether you should keep taking the severe allergic reaction symptoms, such as swelling or trouble breathing, call 911 or your local emergency number right away. These symptoms require immediate medical care because they can become life threatening. If you've had a serious allergic reaction to Spevigo, your doctor may recommend taking a different medication side effectsWhile taking Spevigo, you may be able to take steps to make side effects easier to manage. If you have problems with side effects that do not go away or become worse, talk with your doctor or pharmacist. They can discuss options for managing side effects or other available treatment was a common side effect reported in studies of Spevigo. Steps you can take to manage symptoms associated with this side effect include:using a gentle cleanser or moisturizerapplying a cold compress to the affected areasusing an over-the-counter (OTC) anti-itch medicationUTIUTI was a common side effect reported in studies of Spevigo. Steps you can take to manage symptoms associated with this side effect include:notifying your doctor of any urinary symptomstaking any medications your doctor prescribes as treatmentdrinking plenty of liquids to help flush bacteria from your urinary systemtaking OTC pain medications, such as ibuprofen or acetaminophenPrecautions for SpevigoBefore taking Spevigo, discuss your health history with your doctor. Spevigo may not be right for you if you have certain medical conditions or other factors affecting your health. Be sure to talk with your doctor if any of the following apply to you:active or recurrent infectionstuberculosis (TB)upcoming vaccinationsprevious allergic reaction to this or a similar drugpregnancybreastfeedingDisclaimer: Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.
Bloomberg
6 days ago
- Business
- Bloomberg
Banks Complete Upsized $4.5 Billion Boots Buyout-Debt Sale
Banks sold a larger-than-planned $4.5 billion of debt backing Sycamore Partners ' acquisition of the Boots pharmacy chain, selling $250 million more than intended to a market hungry for new deals. The Boots Group is issuing $3.25 billion -equivalent of leveraged loans across dollars, euros and sterling and a further $1.25 billion -equivalent of high-yield bonds in euros and sterling. The additional $250 million will go toward reducing a preferred equity contribution to the deal, according to people familiar with the situation.
Yahoo
7 days ago
- Business
- Yahoo
CVS Health's Q2 2025 Earnings: What to Expect
Woonsocket, Rhode Island-based CVS Health Corporation (CVS) offers a comprehensive range of healthcare solutions, including pharmacy benefit management services, mail-order pharmacies, retail pharmacies, specialty pharmacies, disease management programs, and retail clinics. Valued at a market cap of $80.7 billion, the company combines clinical expertise, technology, and personalized care to deliver comprehensive health solutions that support better health outcomes and long-term wellness. It is scheduled to announce its fiscal Q2 earnings for 2025 before the market opens on Thursday, Jul. 31. Before this event, analysts project this healthcare solutions provider to report a profit of $1.47 per share, down 19.7% from $1.83 per share in the year-ago quarter. The company has surpassed Wall Street's bottom-line estimates in each of the last four quarters. Its earnings of $2.25 per share in the previous quarter topped the consensus estimates by a notable margin of 31.6%. More News from Barchart Dear Google Stock Fans, Mark Your Calendars for July 23 Dear UnitedHealth Stock Fans, Mark Your Calendars for July 29 Peter Thiel Is Betting Big on This Ethereum Treasury Stock. Should You Buy Shares Now? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For the full year, analysts expect CVS to report EPS of $6.12, up 12.9% from $5.42 in fiscal 2024. Its EPS is expected to further grow 14.4% year-over-year to $7 in fiscal 2026. CVS has gained 6.2% over the past 52 weeks, underperforming the S&P 500 Index's ($SPX) 10.5% return over the same time frame. However, it has outpaced the Health Care Select Sector SPDR Fund's (XLV) 10.4% loss over the same period. On May 1, shares of CVS observed a 4.1% rise after the company reported better-than-expected Q1 results. Its overall revenue improved 7% year-over-year to $94.6 billion, topping the consensus estimates by 1.8%. Moreover, its adjusted EPS of $2.25 advanced 71.8% from the year-ago quarter, exceeding the analyst estimates by a notable margin of 31.6%. Robust revenue and adjusted operating income growth across all of its reportable segments aided its quarterly results. Additionally, CVS raised its fiscal 2025 adjusted EPS guidance in the range of $6 to $6.20, reflecting strong performance across each of its businesses. Wall Street analysts are highly optimistic about CVS' stock, with a "Strong Buy" rating overall. Among 23 analysts covering the stock, 17 recommend "Strong Buy," two indicate "Moderate Buy," and four suggest "Hold.' The mean price target for CVS is $79.55, implying a 24.7% premium from the current levels. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
